All In Biotech

Free tool

FAERS Monitor: Vogelxo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204399 or its brand name (Vogelxo, Testosterone). Reports on generic versions are filed under their own applications.

Reports

19,084

Serious

10,933

57% of reports

Hospitalization

4,603

Death reported

780

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,467
  • off label use1,232
  • fatigue1,182
  • nausea858
  • pain778
  • headache776
  • diarrhoea628
  • anxiety612
  • asthenia598
  • arthralgia595
  • dizziness593
  • dyspnoea549
  • insomnia514
  • weight decreased432
  • depression428

Reports by year received

View as table
YearReports
2004169
2005126
2006139
2007156
2008188
2009248
2010307
2011334
2012875
2013367
2014556
20151,104
20161,061
2017978
20181,138
20191,227
20201,198
20211,206
20221,419
20231,550
20241,641
20251,722
20261,375

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,075 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anxietySignal6122.42.2490
insomniaSignal5142.12.0310
depressionSignal4282.11.9239
asthenia5981.81.6196
weight decreased4321.71.6127
fatigue1,1821.71.6332
arthralgia5951.61.5128
off label use1,2321.61.5251
pain7781.41.390
headache7761.41.377
dizziness5931.31.244
drug ineffective1,4671.21.265
nausea8581.21.128
diarrhoea6281.11.03
dyspnoea5491.11.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.